WHO Recommends Oxford's Malaria Vaccine for Global Rollout

The vaccine's Phase III clinical trial results showed that it had an efficacy of 75% in areas with high seasonal malaria transmission.

Malaria4 0
University of Oxford

Malaria claims over half a million lives each year, but that number will likely see a steep decline in the near future thanks to a vaccine developed by University of Oxford and the Serum Institute of India. A recent University of Oxford article noted that the R21/Matrix-M malaria vaccine has received a recommendation for use from the World Health Organization. The vaccine, after undergoing rigorous evaluation by WHO's experts, has demonstrated high efficacy and safety in clinical trials conducted in multiple countries with varying malaria transmission patterns. 

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026